June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Effectiveness of anti-Tumor Necrosis Factor agents in Pediatric Population with Uveitis
Author Affiliations & Notes
  • Rula Hajj-ali
    Orthopedics and Rheumatologic Institute, Cleveland Clinic Foundation, Cleveland, OH
  • Maria Choudhary
    Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH
  • Andrew Zeft
    Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH
  • Steven Spalding
    Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH
  • Sunil Srivastava
    Ophthalmology, Cleveland Clinic Foundation, Cleveland, OH
  • Careen Lowder
    Ophthalmology, Cleveland Clinic Foundation, Cleveland, OH
  • Footnotes
    Commercial Relationships Rula Hajj-ali, None; Maria Choudhary, None; Andrew Zeft, Pfizer (I), Merck (I); Steven Spalding, None; Sunil Srivastava, Bausch and Lomb (F), Bausch and Lomb (C), Novartis (F), Allergan (F); Careen Lowder, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5191. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rula Hajj-ali, Maria Choudhary, Andrew Zeft, Steven Spalding, Sunil Srivastava, Careen Lowder; Effectiveness of anti-Tumor Necrosis Factor agents in Pediatric Population with Uveitis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5191.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Anti-tumor necrosis factor (anti-TNF) agents play an important role in controlling inflammation associated with non-infectious uveitis. Most commonly used agents include infliximab, adalimumab and etanercept. We compared these three agents in the pediatric population with non-infectious uveitis that is resistant to conventional immunosuppressive therapy.

 
Methods
 

A retrospective chart review of pediatric patients < 18 years old , with non-infectious uveitis followed at Cole Eye Institute between the year 2003 to 2011. All patients with non-infectious uveitis on anti-TNF agents were included in the study. Primary outcomes included achieving sustained remission (SR, defined as absence of inflammation for at least 3 consecutive months on a prednisone (or its equivalent) dose of 10 mg or less), time to SR and duration of SR. Proportional hazard regression model was used for sustained remission analysis where as categorical data was analyzed using the Chi-square tests.

 
Results
 

The study cohort consisted of thirty eight patients consisting of 29 (76.3%) females and 9 (23.7%) males with a mean age of 11.2 (range: 3 - 17) years at the time of start of anti-TNF. Out of these, 23 (60.5%) had anterior uveitis, 4 (10.5%) had intermediate, 3 had posterior (7.9%) and 8 (21.1%) had panuveitis. 5 patients were on etanercept, 21 on infliximab and 12 on adalimumab. The mean duration to achieve SR was 8.46 (SD: 10.3) months for patients on etanercept, 11.42 (SD: 17.24) months on infliximab, and 12.86 (SD: 17.65) months on adalimumab (p = 0.96) (Figure 1). 80% patients on etanercept, 75% on infliximab and 81.3% on adalimumab were able to achieve SR (p = 0.88). SR was maintained for a mean duration of 28.7 (SD: 20.1) months on infliximab, 11.3 (SD: 10.2) months on adalimumab and 12.3 (SD: 6.5) months on etanercept (p = 0.043). The mean dose of infliximab at which SR was achieved was 6.7 mg/kg (SD: 3.1) at mean dosing interval of 3.6 (SD; 2.4) weeks.

 
Conclusions
 

Anti-TNF agents are effective in controlling inflammation in pediatric patients with non-infectious uveitis. Patients on infliximab tend to do better than those on etanercept and adalimumab by maintaining disease control for a longer period.

 
 
Table 1: Kaplan Meier curve showing comparison of the three agents for time to achieve steroid sparing sustained remission.
 
Table 1: Kaplan Meier curve showing comparison of the three agents for time to achieve steroid sparing sustained remission.
 
Keywords: 746 uveitis-clinical/animal model  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×